Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Urology Wiley

Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

Yuasa, Takeshi
International Journal of Urology , Volume 25 (6) – Jan 1, 2018
Download PDF
2 pages

Loading next page...
 
/lp/wiley/editorial-comment-from-dr-yuasa-to-prognostic-impact-of-the-gxViNW08bS
Publisher
Wiley
Copyright
Copyright © 2018 The Japanese Urological Association
ISSN
0919-8172
eISSN
1442-2042
DOI
10.1111/iju.13699
Publisher site
See Article on Publisher Site

Abstract

Journal

International Journal of Urology – Wiley

Published: Jan 1, 2018

References

  • Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer
    Yuasa, T; Takahashi, S; Hatake, K
  • Biomarkers to predict prognosis and response to checkpoint inhibitors
    Yuasa, T; Masuda, H; Yamamoto, S
  • Evaluation of preoperative aspartate transaminase/alanine transaminase ratio as an independent predictive biomarker in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy: a propensity score matching study
    Ishihara, H; Kondo, T; Yoshida, K
  • Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
    Kang, M; Yu, J; Sung, HH